Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped A business decision was made by Pfizer to terminate and remove the Phase 2 expansion of this study for administrative reasons. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.

Conditions

Ovarian Cancer
Ovarian Neoplasms
Ovarian Carcinoma
Fallopian Tube Cancer
Epithelial Ovarian Cancer
Primary Peritoneal Carcinoma

Interventions

DRUG: maplirpacept (PF-07901801)
DRUG: Pegylated Liposomal Doxorubicin (PLD)

Sponsor

Pfizer